CTLA4 and hepatocellular carcinoma: A randomized, open-label, controlled multicenter phase III clinical study (NCT04720716) is currently ongoing to test the efficacy of IBI310, an anti-CTLA-4 monoclonal antibody, in combination with the PD-1 inhibitor sintilimab as a first-line treatment for advanced HCC (details in Table 2).